MS Society Scotland has welcomed the decision to approve the first ever drug for progressive multiple sclerosis (MS) for use on NHS Scotland.
Ocrelizumab (Ocrevus) has been given the green light by the Scottish Medicines Consortium for treating primary progressive MS where the condition is still early in terms of duration and disability and shows evidence of inflammation.
More than 11,000 people in Scotland have MS and around 65 each year are diagnosed with the primary progressive form.
Read more: Former Bankies part of group launching project to open homeless shelter
Ocrelizumab is the first and only treatment that can slow disability progression in this type of MS, where symptoms gradually worsen over time.
Morna Simpkins, director for MS Society Scotland, said: “This is great news and a hugely important development.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article